Home/Pipeline/KRP-297 (Mirogabalin)

KRP-297 (Mirogabalin)

Diabetic Peripheral Neuropathic Pain (DPNP)

Phase IIIActive

Key Facts

Indication
Diabetic Peripheral Neuropathic Pain (DPNP)
Phase
Phase III
Status
Active
Company

About Kissei Pharmaceutical

Kissei Pharmaceutical is a mid-sized, research-driven Japanese pharmaceutical company with a history spanning over 70 years. Its strategic focus lies in developing and marketing novel drugs for urological, nephrological, and metabolic disorders, while also engaging in licensing and collaborative partnerships to expand its portfolio. The company leverages its expertise in drug discovery and development to address unmet medical needs, with a commercial presence in Japan and through international partnerships. Its financial stability is supported by marketed products and a pipeline of clinical-stage candidates.

View full company profile

Other Diabetic Peripheral Neuropathic Pain (DPNP) Drugs

DrugCompanyPhase
LX9211Lexicon PharmaceuticalsPhase 2